Texas Diabetes and Endocrine Trials

Texas Diabetes and Endocrine	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Blevins, Thomas C

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed

141

Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin

Mannkind Corporation, Jaeb Center for Health Research

Diabetes Mellitus, Type 1

03/24

06/24

QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed

730

Europe, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar

Eli Lilly and Company, Eli Lilly and Company

Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

02/24

PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting

Europe, Canada, Japan, US, RoW

Plozasiran, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Familial Chylomicronemia

04/24

04/26

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

905

Europe, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

05/27

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

07/27

TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting

1800

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity, Cardiovascular Diseases

04/26

05/26

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Completed

N/A

319

Canada, US

t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type 2 Diabetes Treated With Insulin

09/24

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Harrison, Lindsay B

ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated

Europe, Canada, US, RoW

EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo

Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.

Non-Alcoholic Steatohepatitis

10/21

11/21

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

Ozer, Kerem

MATILDA, NCT05632276: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds

Completed

N/A

ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive

ConvaTec Inc.

Surgical Wound, Trauma-related Wound

03/24

NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System

Withdrawn

N/A

Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System

ConvaTec Inc.

Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound

10/23

Fields, Cory

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Blevins, Thomas C

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed

141

Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin

Mannkind Corporation, Jaeb Center for Health Research

Diabetes Mellitus, Type 1

03/24

06/24

Completed

730

Europe, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar

Eli Lilly and Company, Eli Lilly and Company

Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

02/24

PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting

Europe, Canada, Japan, US, RoW

Plozasiran, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Familial Chylomicronemia

04/24

04/26

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

905

Europe, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

05/27

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

07/27

TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting

1800

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity, Cardiovascular Diseases

04/26

05/26

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Completed

N/A

319

Canada, US

t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type 2 Diabetes Treated With Insulin

09/24

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Harrison, Lindsay B

ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated

Europe, Canada, US, RoW

EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo

Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.

Non-Alcoholic Steatohepatitis

10/21

11/21

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

Ozer, Kerem

Completed

N/A

ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive

ConvaTec Inc.

Surgical Wound, Trauma-related Wound

03/24

NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System

Withdrawn

N/A

Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System

ConvaTec Inc.

Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound

10/23

Fields, Cory

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25



	Diseases Companies Products Productz Mechanisms of Action Sites